Business Context and Reporting Period
Company: Impact Biomedical Inc.
Filing Type: Form 8-K (Current Report)
Reporting Date: September 16, 2024 (Event Date)
Key Event: Entry into a Material Definitive Agreement for a firm commitment Initial Public Offering (IPO) and subsequent closing of the offering.
Key Financial Metrics and Transaction Details
- Shares Offered: 1,500,000 shares of Common Stock.
- Public Offering Price: $3.00 per share.
- Total Net Proceeds: Approximately $3,764,500.00 (after deducting discounts, expenses allowance, and expenses).
- Listing: NYSE American under the ticker symbol "IBO".
- Trading Commencement: September 16, 2024.
- Representative's Warrants: Issued to purchase 5% of the Common Stock sold in the offering. Exercise price is 125% of the public offering price ($3.75). Exercisable starting 9 months after the offering commencement, expiring on the third anniversary.
Material Changes and Agreements
The Company entered into an Underwriting Agreement with Revere Securities, LLC. The offering closed on September 17, 2024. This filing marks the Company's transition to a publicly traded entity on the NYSE American.
Lock-Up Agreement: The Company, its Directors, Officers, and certain affiliates have agreed to a six-month lock-up period following the effective date of the Registration Statement, prohibiting the sale or disposition of common stock or convertible securities.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the successful pricing and closing of the IPO. The Underwriting Agreement contains customary representations and warranties but explicitly states these are not intended as factual information for investors regarding the current state of affairs; investors are directed to other Commission filings for such details.
Risks and Contingencies: The filing notes the existence of an over-allotment option, though specific details on its exercise are not provided in this text. The Representative's Warrants introduce potential future dilution if exercised.
Investor Verification Checklist
- Verify the final prospectus filed on September 16, 2024, for detailed risk factors and use of proceeds.
- Confirm the exact number of shares issued if the over-allotment option was exercised (not specified in this 8-K).
- Review the full text of the Underwriting Agreement (Exhibit 1.1) for specific indemnification and termination clauses.
- Monitor the NYSE American listing status and trading volume under symbol "IBO" post-September 16, 2024.
- Check for subsequent filings regarding the exercise of the Representative's Warrants after the 9-month waiting period.